Skip to main content
Erschienen in: Quality of Life Research 10/2017

27.06.2017

Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer

verfasst von: Oxana Palesh, Karyn Haitz, Francis Lévi, Georg A. Bjarnason, Carl Deguzman, Igbal Alizeh, Ayhan Ulusakarya, Mary Melissa Packer, Pasquale F. Innominato

Erschienen in: Quality of Life Research | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

Patients with cancers frequently experience sleep and circadian dysfunction. To date, only a few studies have used both a questionnaire and actigraphy for concomitant evaluation of sleep and circadian function in patients with cancer. We sought to evaluate objective sleep and circadian parameters in metastatic colon cancer (MCC) patients and their associations with symptoms and quality of life (QOL).

Methods

Patients reported subjective sleep problems on the EORTC QLQ-C30. Sleep and circadian parameters were calculated using a wrist-actigraph that patients wore for 72 h.

Results

237 Patients with MCC (mean age: 60.4 years; range: 20.7–77.6; Male/Female ratio: 1.66) participated in this cross-sectional study. Subjective sleep problems were reported by 63.4% of patients (S+). No differences in any sleep parameters (sleep efficiency, sleep latency, total sleep time, total time in bed, wake after sleep onset, activity bathyphase) were observed between S+ and S− patients. However, S+ patients displayed a significantly worse circadian function than S− patients (96.4 vs 98.1%; p = 0.005). The presence of poor subjective sleep and objective circadian dysfunction negatively affected symptoms and QOL domains (p = 0.038).

Conclusions

Subjective report of sleep problems was not associated with worse objectively measured sleep parameters in patients with MCC although it was associated with disrupted circadian rest-activity rhythm and poorer QOL. These findings coincide with prior research in cancer patients in that an inconsistent relationship exists between subjective and objective sleep measurements on some sleep domains. This study supports the value of coupled evaluation of self-reported and objective measures of sleep and circadian function in cancer patients.
Literatur
1.
Zurück zum Zitat Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 66(1), 7–30. Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 66(1), 7–30.
2.
Zurück zum Zitat Mazzoccoli, G., Vinciguerra, M., Papa, G., & Piepoli, A. (2014). Circadian clock circuitry in colorectal cancer. World Journal of Gastroenterology, 20(15), 4197–4207.CrossRefPubMedPubMedCentral Mazzoccoli, G., Vinciguerra, M., Papa, G., & Piepoli, A. (2014). Circadian clock circuitry in colorectal cancer. World Journal of Gastroenterology, 20(15), 4197–4207.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Innominato, P. F., Roche, V. P., Palesh, O. G., Ulusakarya, A., Spiegel, D., & Levi, F. A. (2014). The circadian timing system in clinical oncology. Annals of Medicine, 46(4), 191–207.CrossRefPubMed Innominato, P. F., Roche, V. P., Palesh, O. G., Ulusakarya, A., Spiegel, D., & Levi, F. A. (2014). The circadian timing system in clinical oncology. Annals of Medicine, 46(4), 191–207.CrossRefPubMed
4.
Zurück zum Zitat Reppert, S. M., & Weaver, D. R. (2002). Coordination of circadian timing in mammals. Nature, 418(6901), 935–941.CrossRefPubMed Reppert, S. M., & Weaver, D. R. (2002). Coordination of circadian timing in mammals. Nature, 418(6901), 935–941.CrossRefPubMed
5.
Zurück zum Zitat Foster, R. G., & Wulff, K. (2005). The rhythm of rest and excess. Nature Reviews Neuroscience, 6(5), 407–414.CrossRefPubMed Foster, R. G., & Wulff, K. (2005). The rhythm of rest and excess. Nature Reviews Neuroscience, 6(5), 407–414.CrossRefPubMed
6.
Zurück zum Zitat Rajaratnam, S. M., & Arendt, J. (2001). Health in a 24-h society. Lancet, 358(9286), 999–1005.CrossRefPubMed Rajaratnam, S. M., & Arendt, J. (2001). Health in a 24-h society. Lancet, 358(9286), 999–1005.CrossRefPubMed
7.
Zurück zum Zitat Sack, R. L. (2010). Clinical practice. Jet lag. New England Journal of Medicine, 362(5), 440–447.CrossRefPubMed Sack, R. L. (2010). Clinical practice. Jet lag. New England Journal of Medicine, 362(5), 440–447.CrossRefPubMed
8.
Zurück zum Zitat Innominato, P. F., Mormont, M. C., Rich, T. A., Waterhouse, J., Levi, F. A., & Bjarnason, G. A. (2009). Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: Implications for innovative therapeutic approaches. Integrative Cancer Therapy, 8(4), 361–370.CrossRef Innominato, P. F., Mormont, M. C., Rich, T. A., Waterhouse, J., Levi, F. A., & Bjarnason, G. A. (2009). Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: Implications for innovative therapeutic approaches. Integrative Cancer Therapy, 8(4), 361–370.CrossRef
9.
Zurück zum Zitat Molassiotis, A., Wengstrom, Y., & Kearney, N. (2010). Symptom cluster patterns during the first year after diagnosis with cancer. Journal of Pain and Symptom Management, 39(5), 847–858.CrossRefPubMed Molassiotis, A., Wengstrom, Y., & Kearney, N. (2010). Symptom cluster patterns during the first year after diagnosis with cancer. Journal of Pain and Symptom Management, 39(5), 847–858.CrossRefPubMed
10.
Zurück zum Zitat Miller, A. H., Ancoli-Israel, S., Bower, J. E., Capuron, L., & Irwin, M. R. (2008). Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. Journal of Clinical Oncology, 26(6), 971–982.CrossRefPubMedPubMedCentral Miller, A. H., Ancoli-Israel, S., Bower, J. E., Capuron, L., & Irwin, M. R. (2008). Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. Journal of Clinical Oncology, 26(6), 971–982.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Morgenthaler, T. I., Lee-Chiong, T., Alessi, C., Friedman, L., Aurora, R. N., Boehlecke, B., et al. (2007). Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep, 30(11), 1445–1459.CrossRefPubMedPubMedCentral Morgenthaler, T. I., Lee-Chiong, T., Alessi, C., Friedman, L., Aurora, R. N., Boehlecke, B., et al. (2007). Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep, 30(11), 1445–1459.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Palesh, O., Aldridge-Gerry, A., Ulusakarya, A., Ortiz-Tudela, E., Capuron, L., & Innominato, P. F. (2013). Sleep disruption in breast cancer patients and survivors. Journal of the National Comprehensive Cancer Network, 11(12), 1523–1530.CrossRefPubMed Palesh, O., Aldridge-Gerry, A., Ulusakarya, A., Ortiz-Tudela, E., Capuron, L., & Innominato, P. F. (2013). Sleep disruption in breast cancer patients and survivors. Journal of the National Comprehensive Cancer Network, 11(12), 1523–1530.CrossRefPubMed
13.
Zurück zum Zitat Palesh, O. G., Roscoe, J. A., Mustian, K. M., Roth, T., Savard, J., Ancoli-Israel, S., et al. (2010). Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. Journal of Clinical Oncology, 28(2), 292–298.CrossRefPubMed Palesh, O. G., Roscoe, J. A., Mustian, K. M., Roth, T., Savard, J., Ancoli-Israel, S., et al. (2010). Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. Journal of Clinical Oncology, 28(2), 292–298.CrossRefPubMed
14.
Zurück zum Zitat Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., Sprod, L., et al. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151–162.CrossRefPubMedPubMedCentral Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., Sprod, L., et al. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151–162.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Dhruva, A., Paul, S. M., Cooper, B. A., Lee, K., West, C., Aouizerat, B. E., et al. (2012). A longitudinal study of measures of objective and subjective sleep disturbance in patients with breast cancer before, during, and after radiation therapy. Journal of Pain and Symptom Management, 44(2), 215–228.CrossRefPubMedPubMedCentral Dhruva, A., Paul, S. M., Cooper, B. A., Lee, K., West, C., Aouizerat, B. E., et al. (2012). A longitudinal study of measures of objective and subjective sleep disturbance in patients with breast cancer before, during, and after radiation therapy. Journal of Pain and Symptom Management, 44(2), 215–228.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Erren, T. C., Morfeld, P., Foster, R. G., Reiter, R. J., Gross, J. V., & Westermann, I. K. (2016). Sleep and cancer: Synthesis of experimental data and meta-analyses of cancer incidence among some 1 500 000 study individuals in 13 countries. Chronobiology International, 33, 1–26.CrossRef Erren, T. C., Morfeld, P., Foster, R. G., Reiter, R. J., Gross, J. V., & Westermann, I. K. (2016). Sleep and cancer: Synthesis of experimental data and meta-analyses of cancer incidence among some 1 500 000 study individuals in 13 countries. Chronobiology International, 33, 1–26.CrossRef
17.
Zurück zum Zitat Innominato, P. F., Spiegel, D., Ulusakarya, A., Giacchetti, S., Bjarnason, G. A., Lévi, F., & Palesh, O. (2015). Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. Sleep Medicine, 16(3), 391–398. doi:10.1016/j.sleep.2014.10.022.CrossRefPubMed Innominato, P. F., Spiegel, D., Ulusakarya, A., Giacchetti, S., Bjarnason, G. A., Lévi, F., & Palesh, O. (2015). Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. Sleep Medicine, 16(3), 391–398. doi:10.​1016/​j.​sleep.​2014.​10.​022.CrossRefPubMed
18.
Zurück zum Zitat Innominato, P. F., Giacchetti, S., Bjarnason, G. A., Focan, C., Garufi, C., Coudert, B., et al. (2012). Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. International Journal of Cancer, 131(11), 2684–2692.CrossRefPubMed Innominato, P. F., Giacchetti, S., Bjarnason, G. A., Focan, C., Garufi, C., Coudert, B., et al. (2012). Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. International Journal of Cancer, 131(11), 2684–2692.CrossRefPubMed
19.
Zurück zum Zitat Levi, F., Dugue, P. A., Innominato, P., Karaboue, A., Dispersyn, G., Parganiha, A., et al. (2014). Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiology International, 31(8), 891–900.CrossRefPubMed Levi, F., Dugue, P. A., Innominato, P., Karaboue, A., Dispersyn, G., Parganiha, A., et al. (2014). Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival. Chronobiology International, 31(8), 891–900.CrossRefPubMed
20.
Zurück zum Zitat Ancoli-Israel, S., Martin, J. L., Blackwell, T., Buenaver, L., Liu, L., Meltzer, L. J., et al. (2015). The SBSM guide to actigraphy monitoring: Clinical and research applications. Behavioral Sleep Medicine, 13(Suppl 1), S4–S38.CrossRefPubMed Ancoli-Israel, S., Martin, J. L., Blackwell, T., Buenaver, L., Liu, L., Meltzer, L. J., et al. (2015). The SBSM guide to actigraphy monitoring: Clinical and research applications. Behavioral Sleep Medicine, 13(Suppl 1), S4–S38.CrossRefPubMed
21.
Zurück zum Zitat Minors, D., Akerstedt, T., Atkinson, G., Dahlitz, M., Folkard, S., Levi, F., et al. (1996). The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. Chronobiology International, 13(1), 27–34.CrossRefPubMed Minors, D., Akerstedt, T., Atkinson, G., Dahlitz, M., Folkard, S., Levi, F., et al. (1996). The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. Chronobiology International, 13(1), 27–34.CrossRefPubMed
22.
Zurück zum Zitat Natale, V., Innominato, P. F., Boreggiani, M., Tonetti, L., Filardi, M., Parganiha, A., et al. (2015). The difference between in bed and out of bed activity as a behavioral marker of cancer patients: A comparative actigraphic study. Chronobiology International, 32(7), 925–933.CrossRefPubMed Natale, V., Innominato, P. F., Boreggiani, M., Tonetti, L., Filardi, M., Parganiha, A., et al. (2015). The difference between in bed and out of bed activity as a behavioral marker of cancer patients: A comparative actigraphic study. Chronobiology International, 32(7), 925–933.CrossRefPubMed
23.
Zurück zum Zitat Innominato, P. F., Focan, C., Gorlia, T., Moreau, T., Garufi, C., Waterhouse, J., et al. (2009). Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res, 69(11), 4700–4707.CrossRefPubMedPubMedCentral Innominato, P. F., Focan, C., Gorlia, T., Moreau, T., Garufi, C., Waterhouse, J., et al. (2009). Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res, 69(11), 4700–4707.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Mormont, M. C., Waterhouse, J., Bleuzen, P., Giacchetti, S., Jami, A., Bogdan, A., et al. (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clinical Cancer Research, 6(8), 3038–3045.PubMed Mormont, M. C., Waterhouse, J., Bleuzen, P., Giacchetti, S., Jami, A., Bogdan, A., et al. (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clinical Cancer Research, 6(8), 3038–3045.PubMed
25.
Zurück zum Zitat Mormont, M. C., & Waterhouse, J. (2002). Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiology International, 19(1), 313–323.CrossRefPubMed Mormont, M. C., & Waterhouse, J. (2002). Contribution of the rest-activity circadian rhythm to quality of life in cancer patients. Chronobiology International, 19(1), 313–323.CrossRefPubMed
26.
Zurück zum Zitat Chen, H. M., Wu, Y. C., Tsai, C. M., Tzeng, J. I., & Lin, C. C. (2015). Relationships of circadian rhythms and physical activity with objective sleep parameters in lung cancer patients. Cancer Nursing, 38(3), 215–223.CrossRefPubMed Chen, H. M., Wu, Y. C., Tsai, C. M., Tzeng, J. I., & Lin, C. C. (2015). Relationships of circadian rhythms and physical activity with objective sleep parameters in lung cancer patients. Cancer Nursing, 38(3), 215–223.CrossRefPubMed
27.
Zurück zum Zitat Giacchetti, S., Bjarnason, G., Garufi, C., Genet, D., Iacobelli, S., Tampellini, M., et al. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. Journal of Clinical Oncology, 24(22), 3562–3569.CrossRefPubMed Giacchetti, S., Bjarnason, G., Garufi, C., Genet, D., Iacobelli, S., Tampellini, M., et al. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. Journal of Clinical Oncology, 24(22), 3562–3569.CrossRefPubMed
28.
Zurück zum Zitat Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed
29.
Zurück zum Zitat Efficace, F., Innominato, P. F., Bjarnason, G., Coens, C., Humblet, Y., Tumolo, S., et al. (2008). Validation of patient’s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: Results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 26(12), 2020–2026.CrossRefPubMed Efficace, F., Innominato, P. F., Bjarnason, G., Coens, C., Humblet, Y., Tumolo, S., et al. (2008). Validation of patient’s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: Results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. Journal of Clinical Oncology, 26(12), 2020–2026.CrossRefPubMed
30.
Zurück zum Zitat Fayers, P., Bottomley, A., EORTC Quality of Life Group, & Quality of Life Unit. (2002). Quality of life research within the EORTC-the EORTC QLQ-C30 European organisation for research and treatment of cancer. European Journal of Cancer, 38(Suppl 4), S125–S133.CrossRefPubMed Fayers, P., Bottomley, A., EORTC Quality of Life Group, & Quality of Life Unit. (2002). Quality of life research within the EORTC-the EORTC QLQ-C30 European organisation for research and treatment of cancer. European Journal of Cancer, 38(Suppl 4), S125–S133.CrossRefPubMed
31.
Zurück zum Zitat Ancoli-Israel, S., Cole, R., Alessi, C., Chambers, M., Moorcroft, W., & Pollak, C. P. (2003). The role of actigraphy in the study of sleep and circadian rhythms. Sleep, 26(3), 342–392.CrossRefPubMed Ancoli-Israel, S., Cole, R., Alessi, C., Chambers, M., Moorcroft, W., & Pollak, C. P. (2003). The role of actigraphy in the study of sleep and circadian rhythms. Sleep, 26(3), 342–392.CrossRefPubMed
32.
Zurück zum Zitat Palesh, O., Aldridge-Gerry, A., Zeitzer, J. M., Koopman, C., Neri, E., Giese-Davis, J., et al. (2014). Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep, 37(5), 837–842.CrossRefPubMedPubMedCentral Palesh, O., Aldridge-Gerry, A., Zeitzer, J. M., Koopman, C., Neri, E., Giese-Davis, J., et al. (2014). Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. Sleep, 37(5), 837–842.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat American Academy of Sleep Medicine. (2005). International classification of sleep disorders: Diagnostic and coding manual (2nd ed.). Westchester, IL: American Academy of Sleep Medicine. American Academy of Sleep Medicine. (2005). International classification of sleep disorders: Diagnostic and coding manual (2nd ed.). Westchester, IL: American Academy of Sleep Medicine.
34.
Zurück zum Zitat Littner, M., Kushida, C. A., Anderson, W. M., Bailey, D., Berry, R. B., Davila, D. G., et al. (2003). Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: An update for 2002. Sleep, 26(3), 337–341.CrossRefPubMed Littner, M., Kushida, C. A., Anderson, W. M., Bailey, D., Berry, R. B., Davila, D. G., et al. (2003). Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: An update for 2002. Sleep, 26(3), 337–341.CrossRefPubMed
35.
Zurück zum Zitat Moore, C. M., Schmiege, S. J., & Matthews, E. E. (2015). Actigraphy and sleep diary measurements in breast cancer survivors: Discrepancy in selected sleep parameters. Behavioral Sleep Medicine, 13(6), 472–490.CrossRefPubMed Moore, C. M., Schmiege, S. J., & Matthews, E. E. (2015). Actigraphy and sleep diary measurements in breast cancer survivors: Discrepancy in selected sleep parameters. Behavioral Sleep Medicine, 13(6), 472–490.CrossRefPubMed
36.
Zurück zum Zitat de Souza, L., Benedito-Silva, A. A., Pires, M. L., Poyares, D., Tufik, S., & Calil, H. M. (2003). Further validation of actigraphy for sleep studies. Sleep, 26(1), 81–85.CrossRefPubMed de Souza, L., Benedito-Silva, A. A., Pires, M. L., Poyares, D., Tufik, S., & Calil, H. M. (2003). Further validation of actigraphy for sleep studies. Sleep, 26(1), 81–85.CrossRefPubMed
37.
Zurück zum Zitat Berger, A. M., Farr, L. A., Kuhn, B. R., Fischer, P., & Agrawal, S. (2007). Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. Journal of Pain and Symptom Management, 33(4), 398–409.CrossRefPubMedPubMedCentral Berger, A. M., Farr, L. A., Kuhn, B. R., Fischer, P., & Agrawal, S. (2007). Values of sleep/wake, activity/rest, circadian rhythms, and fatigue prior to adjuvant breast cancer chemotherapy. Journal of Pain and Symptom Management, 33(4), 398–409.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Tang, N. K., & Sanborn, A. N. (2014). Better quality sleep promotes daytime physical activity in patients with chronic pain? A multilevel analysis of the within-person relationship. PLoS ONE, 9(3), e92158.CrossRefPubMedPubMedCentral Tang, N. K., & Sanborn, A. N. (2014). Better quality sleep promotes daytime physical activity in patients with chronic pain? A multilevel analysis of the within-person relationship. PLoS ONE, 9(3), e92158.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Di Maio, M., Basch, E., Bryce, J., & Perrone, F. (2016). Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nature Reviews Clinical Oncology, 13(5), 319–325.CrossRefPubMed Di Maio, M., Basch, E., Bryce, J., & Perrone, F. (2016). Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nature Reviews Clinical Oncology, 13(5), 319–325.CrossRefPubMed
40.
Zurück zum Zitat Kyte, D., Reeve, B. B., Efficace, F., Haywood, K., Mercieca-Bebber, R., King, M. T., et al. (2016). International society for quality of life research commentary on the draft European medicines agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Quality of Life Research, 25(2), 359–362.CrossRefPubMed Kyte, D., Reeve, B. B., Efficace, F., Haywood, K., Mercieca-Bebber, R., King, M. T., et al. (2016). International society for quality of life research commentary on the draft European medicines agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies. Quality of Life Research, 25(2), 359–362.CrossRefPubMed
Metadaten
Titel
Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer
verfasst von
Oxana Palesh
Karyn Haitz
Francis Lévi
Georg A. Bjarnason
Carl Deguzman
Igbal Alizeh
Ayhan Ulusakarya
Mary Melissa Packer
Pasquale F. Innominato
Publikationsdatum
27.06.2017
Verlag
Springer International Publishing
Erschienen in
Quality of Life Research / Ausgabe 10/2017
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-017-1617-2

Weitere Artikel der Ausgabe 10/2017

Quality of Life Research 10/2017 Zur Ausgabe